ArticleBMC infectious diseases2026
Development of a new clinical prediction rule for candidaemia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandidaemia is a leading cause of hospital-acquired bloodstream infections, especially in intensive care unit (ICU) patients, and is associated with high mortality and healthcare costs. Prediction rules aid in the identification of patients at risk of developing candidaemia. This study aimed to develop a prediction rule for candidaemia within our population and evaluate its performance against two established rules: the Ostrosky-2 and the Nebraska Medical Center (NMC).
methodsWe conducted a case-control study at a tertiary care center in Mexico City. Data were collected from candidaemia patients and controls matched by sex, age, admission area, and prior hospitalization at a 1:2 ratio, covering the period from 2018 to 2024. Significant risk factors for candidaemia were identified via multivariate logistic regression. By calculating the logistic regression coefficients and the final intercept (B0), we developed the “CandID” rule. The sensitivity, specificity, and predictive values of this rule were compared with those of existing rules.
resultsWe included 146 cases and 292 controls. Abdominal surgery, broad-spectrum antibiotics, candiduria, cirrhosis, central venous catheterization, and solid tumors were identified as risk factors for candidemia in the multivariate analysis and were incorporated into the CandID rule. A cutoff value of ≥ 1.92 demonstrated 80% sensitivity, 63% specificity, a positive predictive value of 52%, and a negative predictive value of 86%, with an area under the curve (AUC) of 0.78. When applied to this population, the Ostrosky-2 rule had a sensitivity of 55%, a specificity of 69%, and an AUC of 0.5, whereas the NMC rule had values of 51%, 72%, and 0.61, respectively.
conclusionsThe CandID rule showed the best performance in predicting candidaemia in our population. However, the single-center retrospective design and internal validation may limit generalizability; prospective multicenter validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.